Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus?
Clinical responses to anti-tumor monoclonal antibody (mAb) treatment have been regarded for many years only as a consequence of the ability of mAbs to destroy tumor cells by innate immune effector mechanisms. More recently, it has also been shown that anti-tumor antibodies can induce a long-lasting...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-08-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fimmu.2017.00950/full |
id |
doaj-48df33cee5db42e6bbb983088034a712 |
---|---|
record_format |
Article |
spelling |
doaj-48df33cee5db42e6bbb983088034a7122020-11-24T22:21:39ZengFrontiers Media S.A.Frontiers in Immunology1664-32242017-08-01810.3389/fimmu.2017.00950281677Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus?Claire Deligne0Claire Deligne1Claire Deligne2Claire Deligne3Benoît Milcent4Benoît Milcent5Benoît Milcent6Nathalie Josseaume7Nathalie Josseaume8Nathalie Josseaume9Jean-Luc Teillaud10Jean-Luc Teillaud11Jean-Luc Teillaud12Sophie Sibéril13Sophie Sibéril14Sophie Sibéril15Cordeliers Research Center, INSERM UMR-S 1138, “Cancer, Immune Control and Escape” Laboratory, Paris, FranceSorbonne Universities, Université Pierre et Marie Curie, UMR-S 1138, Paris, FranceUniversité Paris Descartes, UMR-S 1138, Paris, FranceKennedy Institute of Rheumatology, University of Oxford, Oxford, United KingdomCordeliers Research Center, INSERM UMR-S 1138, “Cancer, Immune Control and Escape” Laboratory, Paris, FranceSorbonne Universities, Université Pierre et Marie Curie, UMR-S 1138, Paris, FranceUniversité Paris Descartes, UMR-S 1138, Paris, FranceCordeliers Research Center, INSERM UMR-S 1138, “Cancer, Immune Control and Escape” Laboratory, Paris, FranceSorbonne Universities, Université Pierre et Marie Curie, UMR-S 1138, Paris, FranceUniversité Paris Descartes, UMR-S 1138, Paris, FranceCordeliers Research Center, INSERM UMR-S 1138, “Cancer, Immune Control and Escape” Laboratory, Paris, FranceSorbonne Universities, Université Pierre et Marie Curie, UMR-S 1138, Paris, FranceUniversité Paris Descartes, UMR-S 1138, Paris, FranceCordeliers Research Center, INSERM UMR-S 1138, “Cancer, Immune Control and Escape” Laboratory, Paris, FranceSorbonne Universities, Université Pierre et Marie Curie, UMR-S 1138, Paris, FranceUniversité Paris Descartes, UMR-S 1138, Paris, FranceClinical responses to anti-tumor monoclonal antibody (mAb) treatment have been regarded for many years only as a consequence of the ability of mAbs to destroy tumor cells by innate immune effector mechanisms. More recently, it has also been shown that anti-tumor antibodies can induce a long-lasting anti-tumor adaptive immunity, likely responsible for durable clinical responses, a phenomenon that has been termed the vaccinal effect of antibodies. However, some of these anti-tumor antibodies are directed against molecules expressed both by tumor cells and normal immune cells, in particular lymphocytes, and, hence, can also strongly affect the host adaptive immunity. In addition to a delayed recovery of target cells, lymphocyte depleting-mAb treatments can have dramatic consequences on the adaptive immune cell network, its rebound, and its functional capacities. Thus, in this review, we will not only discuss the mAb-induced vaccinal effect that has emerged from experimental preclinical studies and clinical trials but also the multifaceted impact of lymphocytes-depleting therapeutic antibodies on the host adaptive immunity. We will also discuss some of the molecular and cellular mechanisms of action whereby therapeutic mAbs induce a long-term protective anti-tumor effect and the relationship between the mAb-induced vaccinal effect and the immune response against self-antigens.http://journal.frontiersin.org/article/10.3389/fimmu.2017.00950/fulladaptive immunityantibody-induced immunogenic cell deathCD20hematologic malignanciesimmunotherapytherapeutic monoclonal antibodies |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Claire Deligne Claire Deligne Claire Deligne Claire Deligne Benoît Milcent Benoît Milcent Benoît Milcent Nathalie Josseaume Nathalie Josseaume Nathalie Josseaume Jean-Luc Teillaud Jean-Luc Teillaud Jean-Luc Teillaud Sophie Sibéril Sophie Sibéril Sophie Sibéril |
spellingShingle |
Claire Deligne Claire Deligne Claire Deligne Claire Deligne Benoît Milcent Benoît Milcent Benoît Milcent Nathalie Josseaume Nathalie Josseaume Nathalie Josseaume Jean-Luc Teillaud Jean-Luc Teillaud Jean-Luc Teillaud Sophie Sibéril Sophie Sibéril Sophie Sibéril Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus? Frontiers in Immunology adaptive immunity antibody-induced immunogenic cell death CD20 hematologic malignancies immunotherapy therapeutic monoclonal antibodies |
author_facet |
Claire Deligne Claire Deligne Claire Deligne Claire Deligne Benoît Milcent Benoît Milcent Benoît Milcent Nathalie Josseaume Nathalie Josseaume Nathalie Josseaume Jean-Luc Teillaud Jean-Luc Teillaud Jean-Luc Teillaud Sophie Sibéril Sophie Sibéril Sophie Sibéril |
author_sort |
Claire Deligne |
title |
Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus? |
title_short |
Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus? |
title_full |
Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus? |
title_fullStr |
Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus? |
title_full_unstemmed |
Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus? |
title_sort |
impact of depleting therapeutic monoclonal antibodies on the host adaptive immunity: a bonus or a malus? |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2017-08-01 |
description |
Clinical responses to anti-tumor monoclonal antibody (mAb) treatment have been regarded for many years only as a consequence of the ability of mAbs to destroy tumor cells by innate immune effector mechanisms. More recently, it has also been shown that anti-tumor antibodies can induce a long-lasting anti-tumor adaptive immunity, likely responsible for durable clinical responses, a phenomenon that has been termed the vaccinal effect of antibodies. However, some of these anti-tumor antibodies are directed against molecules expressed both by tumor cells and normal immune cells, in particular lymphocytes, and, hence, can also strongly affect the host adaptive immunity. In addition to a delayed recovery of target cells, lymphocyte depleting-mAb treatments can have dramatic consequences on the adaptive immune cell network, its rebound, and its functional capacities. Thus, in this review, we will not only discuss the mAb-induced vaccinal effect that has emerged from experimental preclinical studies and clinical trials but also the multifaceted impact of lymphocytes-depleting therapeutic antibodies on the host adaptive immunity. We will also discuss some of the molecular and cellular mechanisms of action whereby therapeutic mAbs induce a long-term protective anti-tumor effect and the relationship between the mAb-induced vaccinal effect and the immune response against self-antigens. |
topic |
adaptive immunity antibody-induced immunogenic cell death CD20 hematologic malignancies immunotherapy therapeutic monoclonal antibodies |
url |
http://journal.frontiersin.org/article/10.3389/fimmu.2017.00950/full |
work_keys_str_mv |
AT clairedeligne impactofdepletingtherapeuticmonoclonalantibodiesonthehostadaptiveimmunityabonusoramalus AT clairedeligne impactofdepletingtherapeuticmonoclonalantibodiesonthehostadaptiveimmunityabonusoramalus AT clairedeligne impactofdepletingtherapeuticmonoclonalantibodiesonthehostadaptiveimmunityabonusoramalus AT clairedeligne impactofdepletingtherapeuticmonoclonalantibodiesonthehostadaptiveimmunityabonusoramalus AT benoitmilcent impactofdepletingtherapeuticmonoclonalantibodiesonthehostadaptiveimmunityabonusoramalus AT benoitmilcent impactofdepletingtherapeuticmonoclonalantibodiesonthehostadaptiveimmunityabonusoramalus AT benoitmilcent impactofdepletingtherapeuticmonoclonalantibodiesonthehostadaptiveimmunityabonusoramalus AT nathaliejosseaume impactofdepletingtherapeuticmonoclonalantibodiesonthehostadaptiveimmunityabonusoramalus AT nathaliejosseaume impactofdepletingtherapeuticmonoclonalantibodiesonthehostadaptiveimmunityabonusoramalus AT nathaliejosseaume impactofdepletingtherapeuticmonoclonalantibodiesonthehostadaptiveimmunityabonusoramalus AT jeanlucteillaud impactofdepletingtherapeuticmonoclonalantibodiesonthehostadaptiveimmunityabonusoramalus AT jeanlucteillaud impactofdepletingtherapeuticmonoclonalantibodiesonthehostadaptiveimmunityabonusoramalus AT jeanlucteillaud impactofdepletingtherapeuticmonoclonalantibodiesonthehostadaptiveimmunityabonusoramalus AT sophiesiberil impactofdepletingtherapeuticmonoclonalantibodiesonthehostadaptiveimmunityabonusoramalus AT sophiesiberil impactofdepletingtherapeuticmonoclonalantibodiesonthehostadaptiveimmunityabonusoramalus AT sophiesiberil impactofdepletingtherapeuticmonoclonalantibodiesonthehostadaptiveimmunityabonusoramalus |
_version_ |
1725770171740585984 |